Document is current
Any future updates will be listed below
-
Authors
Campian, Jian L.
Le, Son B.
Ghiaseddin, Ashley https://orcid.org/0000-0001-5599-4610
Butt, Omar H.
Manektalia, Harshit
Chen, Dongjiang https://orcid.org/0000-0003-4611-3898
Xu, Yifei
Liu, Jingxia https://orcid.org/0000-0002-9434-7907
Rahman, Maryam
Thai, Nathan
Leidig, William A.
Johanns, Tanner
Ansstas, George https://orcid.org/0000-0002-7178-8777
Zhou, Alice Y.
Pugazenthi, Sangami https://orcid.org/0000-0002-5179-5232
Dunn, Gavin P.
Huang, Jiayi https://orcid.org/0000-0002-5153-506X
Chheda, Milan G. https://orcid.org/0000-0001-8282-9098
Kim, Albert H. https://orcid.org/0000-0002-1751-8493
Leuthardt, Eric C. https://orcid.org/0000-0003-4154-3135
Tran, David D. https://orcid.org/0000-0002-2380-8921
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Received: 24 September 2025
Accepted: 3 February 2026
First Online: 26 February 2026
Competing interests
: D.D.T. has research funding from Merck, is a consultant for and received research funding from Monteris Medical, serves as a consultant for Novocure, and has research funding from Novocure, TVax, Novartis, Lacerta Therapeutics, Sarepta, Stemline, and Northwest Biotech for other unrelated work. A.P.G. has received personal honoraria for consultant work from Monteris Medical, Alexion Pharmaceuticals, Servier, ONO Pharma USA, Neosoma, Aptitude Health, Guidepoint, and Novocure. A.P.G. has held personal stock in Viatris Inc. O.H.B. serves on the advisory board for Novocure and as a consultant for Menarini. A.H.K. is a consultant for Monteris Medical and has research funding from Stryker to study a dural substitute, which has no direct relation to this study. J.L.C. received research fundings to support investigator-initiated studies from Merck, Incyte and GI Innovation, which have no direct relation to this study. E.C.L. owns stock in Neurolutions, Face to Face Biometrics, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Aurenar, Petal Surgical, Cordance Medical, and Silent Surgical. He serves as a consultant for Monteris Medical, E15, and Neurolutions. He receives licensing fees from Neurolutions and Sora Neuroscience. Additionally, Washington University owns equity in Neurolutions. M.G.C. receives royalties from UpToDate. The remaining authors declare no competing interests.
